Alzheimer Disease

Disease State Hub

Featured

Agitation in Alzheimer Disease

Agitation in Alzheimer Disease

Dronabinol Reduces Agitation in Patients With Alzheimer Disease

12/11/2024

Anthony Calabro, MA

In an interview with Consultant360, Paul B. Rosenberg, MD, discussed his team’s research on using dronabinol, a legal form of synthetic THC, to treat agitation in patients with Alzheimer disease. What...

12/11/2024

Video

Altered Gut Microbiota a Potential Indicator of Early Alzheimer Disease

11/20/2024

Gautam Dantas, PhD

In this video, Gautam Dantas, PhD, discusses the results of his study, which showed that altered gut bacteria may be an indicator of the earliest stages of Alzheimer disease. He also talks about whether...

11/20/2024

Pop Quiz

Pop Quiz

Hesitancy to See a Health Care Provider After Experiencing Mild Cognitive Impairment

09/27/2024

How reluctant are patients to see a doctor when they notice cognitive issues? Take this pop quiz to test your knowledge!

09/27/2024

Interactive Features

Agitation in Alzheimer Disease

Dronabinol Reduces Agitation in Patients With Alzheimer Disease

12/11/2024

Anthony Calabro, MA

12/11/2024

Pop Quiz

Hesitancy to See a Health Care Provider After Experiencing Mild Cognitive Impairment

09/27/2024

How reluctant are patients to see a doctor when they notice cognitive issues? Take this pop quiz to test your knowledge!

09/27/2024

pop quiz

pop quiz

Non-Memory Concerns in Alzheimer Disease Assessment

06/10/2024

Individuals with Alzheimer disease may present with memory loss or other cognition concerns. Are you familiar with the non-memory symptoms that should determine if a patient needs further cognitive...

06/10/2024

Pop Quiz

The Pathology of Agitation Associated With Alzheimer Dementia

02/22/2024

In their presentation at the Practical Updates in Primary Care 2023 Virtual Series, Craig Chepke, MD, DFAPA, and Kevin Williams, MS, MPAS, PA-C reviewed the pathophysiological mechanisms of agitation...

02/22/2024

poll

poll

Genetic Testing for Epilepsy

12/26/2023

Epilepsy is often genetic and can be passed on to children. Do you believe genetic testing has a role in epilepsy management? Take our poll to voice your opinion!

12/26/2023

Clinical Insights

Video

Altered Gut Microbiota a Potential Indicator of Early Alzheimer Disease

11/20/2024

Gautam Dantas, PhD

11/20/2024

Podcast

Providing Care for a Person With Agitation in Alzheimer Disease: Resources and Education

08/26/2024

Leslie Citrome, MD

In this podcast, Leslie Citrome, MD, MPH, talks about resources and strategies of care that caregivers of people with agitation in Alzheimer disease can implement. He talks about how caregivers can be...

08/26/2024

Sponsored

White paper

Mind the Gap: Strategies to Improve Communication Between Clinical and Nonclinical Audiences Around AAD Symptom Recognition and Diagnosis

08/21/2024

Jeff Cummings, MD, ScD; Carolyn Clevenger, DNP, RN, GNP-BC, FAANP, FGSA, FAAN; Tatyana Gurvich, PharmD, BCGP; Lakelyn Hogan Eichenberger, PhD, MA, MBA; W. Clay Jackson, MD, DipTh; Sean Tunis, MD, MSc; Kate Zhong, MD, MSc, FRCP

Agitation in Alzheimer’s dementia is a serious neuropsychiatric condition that is highly prevalent and underdiagnosed. It contributes to adverse clinical outcomes for people living with Alzheimer’s dementia...

08/21/2024

Nutrition411: The Podcast, Ep. 28

The Impact of Dietary Choices on Alzheimer Disease Prevention

06/17/2024

Lisa Jones, MA, RDN, LDN, FAND

In this podcast episode, Lisa Jones interviews Amylee Amos, PhD, RDN, IFMCP, about research that suggests a potential link between dietary choices and the development or prevention of Alzheimer disease and...

06/17/2024

Video

Human Milk Oligosaccharides in the Prevention, Treatment of Nervous System Diseases

05/07/2024

Alex Martinez

In this video, Alex Martinez discusses research on the use of human milk oligosaccharides (HMOs) in the prevention and treatment of nervous system diseases, such as Alzheimer disease, including the...

05/07/2024

For more on the etiology of Alzheimer disease content, visit our Clinical Update page

The most common type of dementia, Alzheimer disease is a progressive disease that generally begins with mild memory loss and involves parts of the brain that control thought, memory, and language.

For more Alzheimer Disease content, visit the Clinical Insights page

Brain changes may begin 10+ years before symptoms appear. These changes include buildup of proteins that form amyloid plaques and tau tangles. This causes healthy neurons to stop functioning, lose connections with other neurons, and die.

For more neurology content, visit the Resource Center

occupational therapist, neurologist, geriatrician, psychiatrist, primary care physicians, geropsychologist

For more dementia content, visit the Disease State Hub

Memory loss that disrupts daily life
Difficulty completing familiar tasks at home, at work, or at leisure
Worsening judgment
Misplacing items & failure to retrace steps
Changes in mood, personality, or behavior

For more imaging content, visit the Resource Center

There is no single test to determine AD, but testing options include: computed tomography scan, magnetic resonance imaging, positron emission tomography scan, cerebrospinal fluid analysis, neurological examination

For more neurological diseases content, visit the Disease State Hub

Examples of cognitive, functional, and behavioral tests include: Ascertain Dementia 8, Activities Questionnaire, Mini-Cog Mini-Mental State Examination, Montreal Cognitive Assessment, Neuropsychiatric Inventory Questionnaire

For more traumatic brain injury content, visit the Resource Center

Age
Family history
Genetics
Mild cognitive impairment
Modifiable risk factors, like obesity, high cholesterol, poorly controlled type 2 diabetes

For more polls and quizzes, visit the interactive features page

An estimated 6.7 million Americans aged 65 years or older are living with AD (73% are aged 75 years or older)

For more patient education content, visit the Resource Center

By 2025, the number of people aged 65 or older with AD is projected to reach 7.2 million — a 7% increase from 2023.

Research Summaries

Conference Coverage

Are There Correlations Between Depression and Neuropsychiatric Symptoms at the Time of Alzheimer Disease Dementia Diagnosis?

09/23/2024

Jessica Ganga

Using data from the National Alzheimer’s Coordinating Center, a team of researchers investigated any correlations between neuropsychiatric and depressive symptoms at AD dementia diagnosis. Their findings...

09/23/2024

Research Summary

Study: Association Between Maternal History of Severe Memory Impairment and Alzheimer Disease

08/02/2024

Anthony Calabro, MA

Researchers investigated whether parental history of memory issues was associated with amyloid-beta burden in cognitively unimpaired older adults.

08/02/2024

Research Summary

Relationship Between Neuropsychiatric Symptoms in Patients With Alzheimer Disease and Functional Decline

07/29/2024

Jessica Ganga

Researchers evaluated the association between neuropsychiatric symptoms, such as agitation and apathy, in patients with Alzheimer disease and the rate of functional decline.

07/29/2024

Research Summary

Self-, Partner-Reported Cognitive Decline Associated With Greater Tau, β-Amyloid Levels

06/21/2024

Anthony Calabro, MA

Researchers set out to determine the associations between self- and partner-reported cognitive decline and tau and β-amyloid levels among cognitively unimpaired individuals.

06/21/2024

Conference Coverage

Dextromethorphan-Bupropion Delays Relapse of Agitation Symptoms in Patients Diagnosed With Probable Alzheimer Disease

04/29/2024

Anthony Calabro, MA

Researchers evaluated the safety and efficacy of dextromethorphan-bupropion, an FDA approved treatment of major depression disorder, for Alzheimer disease-related agitation. This study was presented at the...

04/29/2024

November 2024

Current Issue

November 2024

Sources

CDC.gov
2023 Alzheimer's Facts and Figures